Evidence map›Paper›PMID 38879768›Full record

ReviewCardiovascular & hematological disorders drug targets2024

Thrombosis in Myeloid Malignancies: From CHIP to AML.

Beatrice Borsellino, Carlos Bravo-Perez, Valeria Visconte, Luca Guarnera

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular & hematological disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Beatrice BorsellinoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 00133, Italy.
Carlos Bravo-PerezDepartment of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH44195, USA.
Valeria VisconteDepartment of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH44195, USA.
Luca GuarneraDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 00133, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of myeloid malignancies is a multi-step process starting from pre-malignant stages. Large-scale studies on clonal hematopoiesis of indeterminate potential (CHIP) identified this condition as a risk factor for developing hematologic malignancies, in particular myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In parallel, CHIP was found to confer an enhanced thrombotic risk, in particular for cardiovascular diseases. In a similar fashion, in recent years, alongside their life-threatening features, increasing attention has been drawn toward thrombotic complications in myeloid malignancies. Thus, the purpose of this review is to gather a growing body of evidence on incidence, pathogenesis and clinical impact of thrombosis in myeloid malignancies at every step of malignant progression, from CHIP to AML.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesThrombosisClonal HematopoiesisHumansRisk Factorsacute myeloid leukemiaacute promyelocytic leukemia.clonal hemopoiesis of indeterminate potentialmyelodysplastic syndromesThrombosisVEXAS syndrome

Identifiers

PMID38879768

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.